Navigation Links
ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/6/2011

MOUNTAIN VIEW, Calif., Jan. 6, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at J.P. Morgan's 29th Annual Healthcare Conference on Wednesday, January 12, 2011, at 10:00 a.m. Pacific at the Westin St. Francis Hotel in San Francisco, CA.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial. Phase III clinical trials of Traficet-EN are expected to initiate in the first quarter 2011. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus and associated complications; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011; and CCX832, a ChemR23 antagonist in Phase I clinical development. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
2. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
3. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
4. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
7. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
8. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
9. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
10. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
11. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... has announced the addition of the "Ovarian Cancer Drugs Price Analysis ... The latest research Ovarian Cancer Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: ... clinical attributes? How are they positioned in the Global Ovarian Cancer market? ...
(Date:2/28/2017)... , Feb. 28, 2017  Rigel Pharmaceuticals, Inc. (Nasdaq: ... will report its fourth quarter and year end ... 7, 2017.  Rigel senior management will follow the ... at 5:00pm Eastern Time (2:00pm Pacific Time) to ... access the live conference call by dialing 855-892-1489 ...
(Date:2/28/2017)... FRANCISCO , February 27, 2017 ... D BioMedical assets for ... LOI contemplates capital infusion into Amarantus ...   Amarantus names four new appointees to its Board of ... SeD Biomedical Inc. (SeD Biomedical) , a ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... In 2014, Harvard researchers published ... approximately 800 deaths from prostate cancer, the researchers found that men who had undergone ... to get fatal prostate cancer. Although the increased risks are small, they seem to ...
(Date:2/28/2017)... Pekin, IL (PRWEB) , ... February 28, 2017 ... ... over the past decade, has challenges as they transition from military to civilian ... population of over two million who experience poorer health and greater occurrence of ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Robert E. ... large medical group. But his impoverished upbringing and life experiences could have led him ... a Physician: Insightful and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares ...
(Date:2/27/2017)... ... February 27, 2017 , ... Orange County dentist, Dr. A. Rassouli, ... that occurs when the bacteria in plaque infect the gums and other tissues supporting ... and root planing or SRP, and can include surgical therapies if the condition has ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine ... programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce ... hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab and ...
Breaking Medicine News(10 mins):